Lifecore Biomedical Inc(LFCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 9.6% | Shs Outstand | 37.7M | Perf Week | 2.35% |
| Market Cap | 0.25B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 34.3M | Perf Month | -0.91% |
| Enterprise Value | 0.44B | PEG | - | EPS next Q | - | Inst Own | 75.56% | Short Float | 5.26% | Perf Quarter | 47.51% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | -0.06% | Short Ratio | 5.08 | Perf Half Y | 28.6% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 1.80M | Perf YTD | -20.29% |
| Book/sh | -0.9 | P/C | 14.34 | EPS past 3/5Y | 31.55% 0.55% | ROE | - | 52W High | -27.39% ($8.98) | Perf Year | -7.65% |
| Cash/sh | 0.45 | P/FCF | - | Sales past 3/5Y | 5.02% -26.24% | ROIC | - | 52W Low | 79.86% ($3.62) | Perf 3Y | -7.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -430.88% | Gross Margin | - | Volatility(W/M) | 0.91% 0.76% | Perf 5Y | -32.92% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | -50.98% |
| Dividend Ex-Date | - | Quick Ratio | 2.69 | EPS Q/Q | -243.04% | Profit Margin | - | RSI (14) | 74.64 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.87 | Sales Q/Q | -6.25% | SMA20 | 1.29% ($6.44) | Beta | 0.99 | Target Price | $6.28 |
| Payout | - | Debt/Eq | 9.72 | Earnings | 2026/8/5 | SMA50 | 21.09% ($5.38) | Rel Volume | 0.68 | Prev Close | $6.51 |
| Employees | - | LT Debt/Eq | 9.64 | EPS/Sales Surpr. | 7.44% 18.47% | SMA200 | 18.15% ($5.52) | Avg Volume(3M) | 0.35M | Price | $6.52 |
| IPO | 1996/2/15 | Option/Short | Yes/Yes | Trades | 1148 | Volume | 240,912 | Change | 0.15% |
💉 LifeCore Biomedical (LFCR) is a U.S. healthcare company built around two core pillars: contract development and manufacturing of injectables, and the production of injectable hyaluronic acid. The company specializes in aseptic filling and finishing of sterile injectables in syringes, vials, and cartridges, along with complex formulation development. It is a specialized player in the branded and generic pharmaceutical space, leveraging long-cultivated expertise in manufacturing premium-grade injectable hyaluronic acid.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded less than usual. That is 68% of its average volume.
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -32.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 75.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
ORR Militia Long/Short Equity ETF <0.01% 
OPPJ WisdomTree Trust WisdomTree Japan Opportunities Fund <0.01% 
DFJ WisdomTree Japan SmallCap Dividend Fund <0.01% 
FDTS First Trust Developed Markets ex-US Small Cap AlphaDEX Fund <0.01% 
JIVE JPMorgan International Value ETF <0.01% It ranks #48 of 83 in the industry
Based on market cap of $247M.
CGC#45 Canopy Growth Corp $283M PER - 
BIOA#46 BioAge Labs Inc $273M PER - 
ACB#47 Aurora Cannabis Inc $268M PER - LFCR#48 Lifecore Biomedical Inc $247M PER - 
SIGA#49 SIGA Technologies Inc $228M PER - 
FAQ
What kind of company is LFCR?
LFCR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of LFCR?
The market cap of LFCR is approximately $247M, ranking 3,852 within its sector.
What is the 52-week high and low for LFCR?
LFCR has recorded a 52-week high of $8.98 and a low of $3.62.
